Pharma Journalist -

Gilead Sciences has announced a definitive agreement to acquire Ouro Medicines, a privately held firm focused on developing T cell engager therapies for autoimmune diseases. The move…
Read More...

Quotient Therapeutics has entered a multi-year research collaboration with Merck & Co.—known as MSD outside the United States and Canada—to identify new drug targets for…
Read More...

Viz.ai has announced a strategic partnership with Alnylam Pharmaceuticals aimed at improving the early detection and diagnosis of cardiac amyloidosis, a serious and often underdiagnosed…
Read More...

UCB has announced plans to establish a major new biologics manufacturing facility in Gwinnett County, Georgia, marking a significant step in the company’s long-term U.S. expansion…
Read More...

Zealand Pharma has announced plans to establish a new research hub in Cambridge, Massachusetts, marking a significant expansion of its global footprint and reinforcing its ambitions in…
Read More...

Kali Therapeutics has entered into a licensing agreement with Sanofi for the development of a novel tri-specific T-cell engager, KT501, aimed at treating a broad range of B…
Read More...

LGM Pharma has announced a $9 million expansion across its U.S. manufacturing network, marking the second phase of a broader contract development and manufacturing organization (CDMO)…
Read More...

Excalipoint Therapeutics has secured an oversubscribed $68.7 million seed financing round to accelerate the development of its next-generation T-cell engager (TCE) therapies, marking…
Read More...

The Medicines and Healthcare products Regulatory Agency (MHRA) and National Institute for Health and Care Excellence (NICE) have unveiled a new collaborative framework aimed at speeding…
Read More...

Novartis has announced a strategic agreement with Synnovation Therapeutics, LLC to acquire SNV4818, an investigational oral therapy designed to treat hormone receptor-positive,…
Read More...